Assessment of the genotoxic potential of a migraine-specific drug by comet and cytokinesis-block micronucleus assays


ÇAYIR A. , ÇOBANOĞLU H. , Coskun M.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, cilt.16, ss.441-446, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 16 Konu: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/17425255.2020.1748598
  • Dergi Adı: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
  • Sayfa Sayıları: ss.441-446

Özet

Background: Eletriptan is a migraine-specific drug-containing the triptan group. In terms of drug safety, the present study aimed to investigate the genotoxic potential of eletriptan. Research design & methods: We conducted our study by using the cytokinesis-block micronucleus cytome (CBMN) assay, a comprehensive method for measuring micronucleus formation, and a sensitive method for detecting DNA-strand breaks. In the assay, cytokinesis-block proliferation index and the frequency of micronuclei were evaluated in lymphocytes treated with three different concentrations (1, 10 and 25 mu g/ml) of eletriptan for 48 hours. In comet assays, DNA damage was evaluated in leucocytes treated with three different concentrations (1, 10 and 25 mu g/ml) of eletriptan for an hour. Results: Eletriptan did not induce cytotoxicity nor any increased micronuclei frequencies. While the comet parameters % DNA in tail, tail moment, and the olive moment was found to be significantly increased at 10 and 25 mu g/ml, the cytokinesis-block proliferation index values were not. Conclusion: These findings suggest that eletriptan is non-cytotoxic but potentially weakly genotoxic at higher concentrations (10 and 25 mu g/ml).